natgillin/translations-raw huggingface dataset:
The final efficacy analysis included all randomised patients (197 CHOP, 202 R-CHOP), and had a median follow-up duration of approximately 31 months. 
Končna analiza učinkovitosti je vključevala vse randomizirane bolnike (197 CHOP, 202 R-CHOP),
If you are having Ritemvia with other medicines, some of the side effects you may get may be due to the other medicines. 
Če prejemate zdravilo Ritemvia skupaj z drugimi zdravili, se nekateri neželeni učinki lahko pojavijo zaradi drugih zdravil.
The two adverse events that were reported were flu-like symptoms, with a dose of 1.8 g of rituximab and fatal respiratory failure, with a dose of 2 g of rituximab. 
Dva opisana neželena dogodka sta bila gripi podobni simptomi (pri odmerku 1,8 g rituksimaba) in odpoved dihal s smrtnim izidom (pri odmerku 2 g rituksimaba).
• The need to monitor patients for infections, especially PML, during and after Ritemvia treatment 
• informacije o nujnosti, da bolnike spremljajo zaradi nastanka mogočih okužb, posebno progresivne multifokalne levkoencefalopatije (PML), med zdravljenjem z zdravilom Ritemvia in po njem,
The analysis of overall survival showed a significant benefit of R-FC treatment over FC chemotherapy alone (p=0.0319, log-rank test) (Table 10a). 
Analiza celokupnega preživetja je pokazala signifikantno korist zdravljenja R-FC glede na samo kemoterapijo FC (p=0,0319, test log rank) (preglednica 10a).
Data from extended follow-up of patients in the study (median follow-up 9 years) confirmed the long-term benefit of rituximab maintenance therapy in terms of PFS, EFS, TNLT and TNCT (Table 
Podatki iz podaljšanega spremljanja bolnikov v študiji (mediana spremljanja 9 let) so potrdili dolgoročno korist vzdrževalnega zdravljenja z zdravilom rituksimab glede na PFS, EFS, TNLT in TNCT (preglednica
18-months p = 0.016 
18 mesecev p = 0,016
Disease activity outcomes 
Vpliv na aktivnost bolezni
late neutropenia3 
pozna nevtropenija3
Patients with a history of a serious infusion reaction to a biologic therapy for RA were excluded from entry. 
Bolniki, ki so imeli v anamnezi resno reakcijo, povezano z infuzijo, na biološko zdravilo za zdravljenje revmatoidnega artritisa, v študijo niso bili vključeni.
Occurred at various times up to several months after completion of rituximab therapy 
Pojavili so se različno, tudi do nekaj mesecev po končanem zdravljenju z rituksimabom.
NR: not reached; a: only applicable to patients achieving a CR 
NR: ni doseženo; a: velja le za bolnike, ki so dosegli CR (popolni odgovor)
Nearly all infusion-related reactions were mild to moderate. 
Skoraj vse z infundiranjem povezane reakcije so bile blage do zmerne.
Rarely fatal cases reported 5 signs and symptoms of cranial neuropathy. 
5 Znaki in simptomi kranialne nevropatije.
A total of 117 patients (88 with GPA, 24 with MPA, and 5 with renal-limited ANCA-associated vasculitis) in disease remission were randomised to receive azathioprine (59 patients) or rituximab (58 patients) in a prospective, multi-center, controlled, open-label study. 
Skupno 117 bolnikov (88 z GPA, 24 z MPA in 5 z ledvično omejenim z ANCA povezanim vaskulitisom), ki so bili v remisiji bolezni, so v prospektivni, multicentrični, kontrolirani odprti študiji randomizirali na prejemanje azatioprina (59 bolnikov) ali rituksimab (58 bolnikov).
Reactivation of hepatitis B infection has also been very rarely reported in rheumatoid arthritis patients receiving rituximab (see section 4.4). 
reaktivaciji okužbe z virusom hepatitisa B so zelo redko poročali tudi pri bolnikih z revmatoidnim artritisom, ki so prejemali rituksimab (glejte poglavje 4.4).
• heart problems - such as reduced heart rate or chest pain (angina) 
težave s srcem - na primer upočasnjen srčni utrip ali bolečina v prsih (angina pektoris),
In Trial 1, conducted in patients with inadequate response or intolerance to one or more TNF inhibitor therapies, receiving rituximab in combination with methotrexate demonstrated significantly less radiographic progression than patients originally receiving methotrexate alone at 56 weeks. 
V preskušanju 1 je bilo pri bolnikih, ki so nezadovoljivo odgovorili na eno ali več zdravljenj z zaviralci TNF ali jih niso prenašali, in ki so prejemali rituksimab in metotreksat, po 56 tednih na posnetkih značilno manj znakov napredovanja kot pri tistih, ki so prvotno dobivali samo metotreksat.
The benefit in terms of PFS was observed in almost all patient subgroups analysed according to disease risk at baseline. 
Korist v smislu preživetja brez napredovanja bolezni so opažali pri skoraj vseh podskupinah, ki so jih analizirali glede na tveganje bolezni pred vključitvijo.
All of these arrhythmias either occurred in the context of a rituximab infusion or were associated with predisposing conditions such as fever, infection, acute myocardial infarction or pre-existing respiratory and cardiovascular disease. 
Vse motnje srčnega ritma so se pojavile v povezavi z infuzijo rituksimaba ali pa so bile povezane s predispozicijskimi stanji, kot so zvišana telesna temperatura, okužba, akutni miokardni infarkt ali predhodna respiratorna ali kardiovaskularna bolezen.
Initial treatment, weekly for 8 doses 
Začetno zdravljenje, 8 odmerkov, enkrat na teden
Data from extended follow-up of patients in the study (median follow-up 9 years) confirmed the longterm benefit of rituximab maintenance therapy in terms of PFS, EFS, TNLT and TNCT (Table 7). 
Podatki iz podaljšanega spremljanja bolnikov v študiji (mediana spremljanja 9 let) so potrdili dolgoročno korist vzdrževalnega zdravljenja z zdravilom rituksimab glede na PFS, EFS, TNLT in TNCT (preglednica 7).
Additional reactions reported in some cases were myocardial infarction, atrial fibrillation, pulmonary oedema and acute reversible thrombocytopenia. 
Dodatne reakcije, o katerih so poročali v nekaterih primerih, so miokardni infarkt, atrijska fibrilacija, pljučni edem in akutna reverzibilna trombocitopenija.
The benefit in terms of PFS was consistently observed in most patient subgroups analysed according to disease risk at baseline (i.e. Binet stages A-C) (Table 10b). 
Korist v smislu preživetja brez napredovanja bolezni so konsistentno opažali pri večini podskupin, ki so jih analizirali glede na tveganje bolezni pred vključitvijo (npr. stopnjo po Binetu A-C) (preglednica 10b).
• you have ever had or might now have a hepatitis infection. 
• če ste kdaj imeli okužbo z virusom hepatitisa, ali če menite, da jo imate zdaj.
In the overall experience of rituximab repeat treatment over one year in rheumatoid arthritis, the proportions of patients with positive antibody titres against S. pneumoniae, influenza, mumps, rubella, varicella and tetanus toxoid were generally similar to the proportions at baseline. 
Pri ponovnem enoletnem zdravljenju z rituksimabom pri revmatoidnem artritisu so bili deleži bolnikov s pozitivnim titrom protiteles proti S. pneumoniae, influenci, mumpsu, rdečkah, noricah in tetanusnem toksoidu na splošno podobni kot izhodiščni.
Following induction of remission with other standard of care immunosuppressants, Ritemvia maintenance treatment should be initiated during the 4 week period that follows disease remission. 
Po indukciji remisije z drugimi imunosupresivi, ki spadajo v okvir običajnega zdravljenja, je treba vzdrževalno zdravljenje z zdravilom Ritemvia začeti v 4-tedenskem obdobju po remisiji bolezni.
• low numbers of platelets in the blood 
nizko število trombocitov v krvi,
Based on the population pharmacokinetic analysis of data in 97 patients with granulomatosis with polyangiitis and microscopic polyangiitis who received 375 mg/m2 rituximab once weekly for four doses, the estimated median terminal elimination half-life was 23 days (range, 9 to 49 days). 
Na podlagi populacijske farmakokinetične analize podatkov 97 bolnikov z granulomatozo s poliangiitisom in z mikroskopskim poliangiitisom, ki so štiri tedne prejemali 375 mg/m2 rituksimaba enkrat na teden, je ocenjeni mediani končni razpolovni čas izločanja 23 dni (razpon: od 9 do 49 dni).
• The need to provide patients with the Patient Alert Card with each infusion 
• informacije o nujnosti, da opozorilno kartico izročijo bolniku ob vsakem infundiranju.
At this time, the infusion can be initially resumed at not more than one-half the previous rate. 
Hitrost infuzije naj na začetku ne bo večja od polovice predhodne.
Concentrate for solution for infusion 500 mg / 50 mL 
koncentrat za raztopino za infundiranje 500 mg/50 ml
• The need to carry the card at all times and to show the card to all treating health care professionals 
• informacije o nujnosti, da jo imajo bolniki s sabo ves čas in da jo pokažejo vsem zdravnikom, ki jih zdravijo,
A higher proportion of patients receiving the original rituximab/MTX treatment also had no erosive progression over 56 weeks (Table 13). 
Prav tako pri večjem deležu bolnikov, ki so prvotno prejemali rituksimab in metotreksat, ni prišlo do napredovanja erozij v 56 tednih (preglednica 13).
During the treatment course in studies with rituximab in combination with chemotherapy, grade 3/4 leucopenia (R-CHOP 88% vs. CHOP 79%, R-FC 23% vs. FC 12%), neutropenia (R-CVP 24% vs. CVP 14%; R-CHOP 97% vs. CHOP 88%, R-FC 30% vs. FC 19% in previously untreated CLL), pancytopenia (R-FC 3% vs. FC 1% in previously untreated CLL) were usually reported with higher frequencies when compared to chemotherapy alone. 
Med zdravljenjem v študijah rituksimaba v kombinaciji s kemoterapijo sta bili 3. ali 4. stopnja levkopenije (R-CHOP 88% v primerjavi s CHOP 79%, R-FC 23% v primerjavi s FC 12%), nevtropenije (R-CVP 24% v primerjavi s CVP 14%, R-CHOP 97% v primerjavi s CHOP 88%, R-FC: 30% v primerjavi s FC 19% pri predhodno nezdravljeni KLL), pancitopenije (R-FC: 3% v primerjavi s FC 1% pri predhodno nezdravljeni KLL) po navadi pogostejši kot s kemoterapijo samo.
In patients with non-Hodgkin's lymphoma receiving rituximab in combination with cytotoxic chemotherapy, cases of hepatitis B reactivation have been reported (see non-Hodgkin's lymphoma). 
Pri bolnikih z ne-Hodgkinovim limfomom, ki so prejemali rituksimab v kombinaciji s citotoksično kemoterapijo, so poročali o primerih reaktivacije virusa hepatitisa B (glejte ne-Hodgkinov limfom).
Trials of rituximab in patients with early arthritis (patients without prior methotrexate treatment and patients with an inadequate response to methotrexate, but not yet treated with TNF-alpha inhibitors) have met their primary endpoints. 
V preskušanjih z rituksimabom pri bolnikih z zgodnjim artritisom (bolniki, ki se še niso zdravili z metotreksatom in bolniki z nezadostnim odzivom na metotreksat, ki se še niso zdravili z zaviralci TNFalfa) so bili primarni cilji doseženi.
B-lymphocytes are involved in the cause of these conditions. 
V nastanek teh bolezni so vpleteni limfociti B.
In the clinical trial studying induction of remission with severe active GPA and MPA, IRRs were defined as any adverse event occurring within 24 hours of an infusion and considered to be infusion-related by investigators in the safety population. 
V kliničnem preskušanju, v katerem so proučevali indukcijo remisije pri hudi aktivni GPA in MPA, so bile z infuzijo povezane reakcije (IRR - infusion-related reactions) opredeljene kot neželeni učinki, ki so se pojavili v 24 urah po infuziji in so jih raziskovalci v varnostni populaciji ocenili kot povezane z infuzijo.
In patients with granulomatosis with polyangiitis (Wegener's) or microscopic polyangiitis in disease remission or pemphigus vulgaris, premedication with 100 mg intravenous methylprednisolone should be completed 30 minutes prior to Ritemvia infusions to decrease the incidence and severity of infusion related reactions (IRRs). 
Pri bolnikih z granulomatozo s poliangiitisom (Wegenerjevo granulomatozo), mikroskopskim poliangiitisom v remisiji ali navadnim pemfigusom je treba 30 minut pred pričetkom infundiranja zdravila Ritemvia zaključiti z intravenskim dajanjem 100 mg metilprednizolona za zmanjšanje incidence in resnosti reakcij, povezanih z infuzijo.
Patients received 2 x 1000 mg intravenous infusions of rituximab or placebo in combination with MTX. 
Bolniki so prejeli dve intravenski infuziji po 1000 mg rituksimaba ali placeba v kombinaciji z metotreksatom.
In patients treated with cyclophosphamide (followed by azathioprine for maintenance of complete remission), 39% of patients achieved CR at 12 months, and 33% of patients achieved CR at 18 months. 
Med bolniki, zdravljenimi s ciklofosfamidom (ki mu je sledil azatioprin za vzdrževanje popolne remisije) je 39 % bolnikov doseglo popolno remisijo po 12 mesecih in 33 % bolnikov po 18 mesecih.
In placebo-controlled periods of clinical trials, 0.94% (13/1382) of rituximab treated patients and 0.27% (2/731) of placebo-treated patients developed severe neutropenia. 
V kliničnih preskušanjih, nadzorovanih s placebom, je pri 0,94 % (13/1382) bolnikov, zdravljenih z rituksimabom in pri 0,27 % (2/731) bolnikov, ki so prejemali placebo, prišlo do razvoja hude nevtropenije.
40% of patients with bone marrow involvement responded compared to 59% of patients with no bone marrow involvement (p=0.0186). 
Na zdravljenje se je odzvalo 40 % bolnikov z infiltracijo kostnega mozga v primerjavi z 59 % bolnikov brez infiltracije kostnega mozga (p = 0,0186).
Cases of hepatitis B reactivation, have been reported, the majority of which were in patients receiving rituximab in combination with cytotoxic chemotherapy. 
Poročali so o reaktivaciji virusa hepatitisa B, večinoma pri bolnikih, ki so prejemali rituksimab v kombinaciji s citotoksično kemoterapijo.
During the treatment period (induction treatment phase comprising of R-CHOP for at most eight cycles), four patients (2%) treated with R-CHOP, all with cardiovascular risk factors, experienced thromboembolic cerebrovascular accidents during the first treatment cycle. 
Med obdobjem zdravljenja (faza indukcijskega zdravljenja, ki je obsegalo R-CHOP vsaj osem ciklov) so se pri štirih bolnikih (2%), zdravljenih z R-CHOP, ki so vsi imeli kardiovaskularne dejavnike tveganja,
In the clinical trial on induction of remission, which included 99 rituximab-treated patients, the overall rate of infection was approximately 237 per 100 patient years (95% CI 197-285) at the 6month primary endpoint. 
V kliničnem preskušanju indukcije remisije, v katerega so prejeli vključili 99 bolnikov, zdravljenih rituksimab, je bil celotni delež okužb na primarni končni točki po 6 mesecih približno 237 na 100 bolnik let (95-% interval zaupanja, 197-285).
Blood and lymphatic system disorders neutropenia1 
Bolezni krvi in limfatičnega sistema nevtropenija1
• The need to advise patients on the risk of infections and PML, including the symptoms to be aware of and the need to contact their doctor immediately if they experience any. 
• informacije o nujnosti svetovanja bolnikom glede tveganja za okužbe in PML, vključno s simptomi, na katere naj bodo pozorni, in informacije o nujnosti, da nemudoma obvestijo svojega zdravnika, če izkusijo katerega od simptomov,
Severe cytokine release syndrome is characterised by severe dyspnoea, often accompanied by bronchospasm and hypoxia, in addition to fever, chills, rigors, urticaria, and angioedema. 
Za hud sindrom sproščanja citokinov je značilna huda dispneja, ki jo pogosto spremljata bronhospazem in hipoksija, poleg zvišane telesne temperature, mrzlice, drgetanja, urtikarije in angioedema.
Experience from pemphigus vulgaris 
Navadni pemfigus (pemphigus vulgaris)
+myocardial infarction4 and 6, arrhythmia, +atrial fibrillation, 
+miokardni infarkt4 in 6, aritmija, +atrijska fibrilacija, tahikardija,
Ritemvia is used for the treatment of granulomatosis with polyangiitis (formerly called Wegener's granulomatosis) or microscopic polyangiitis, taken in combination with corticosteroids. 
Zdravilo Ritemvia se uporablja za zdravljenje granulomatoze s poliangiitisom (prej imenovane Wegenerjeva granulomatoza) ali mikroskopskega poliangiitisa; daje se v kombinaciji s kortikosteroidi.
In the rituximab group, 48% of patients achieved CR at 12 months, and 39% of patients achieved CR at 18 months. 
V skupini, ki je prejemala rituksimab, je 48 % bolnikov doseglo popolno remisijo po 12 mesecih in 39 % bolnikov po 18 mesecih.
These are often colds, but there have been cases of pneumonia or urinary infections. 
Te okužbe so pogosto prehladi, opisani pa so bili tudi primeri pljučnice in okužb sečil.
The overall safety profile was consistent with the well-established safety profile for rituximab in approved autoimmune indications, including GPA/MPA. 
Na splošno so se varnostne značilnosti ujemale z dobro znanimi varnostnimi značilnostmi rituksimab pri odobrenih avtoimunskih indikacijah, vključno z GPA/MPA.
They were characterised by pulmonary events and in some cases included rapid tumour lysis and features of tumour lysis syndrome in addition to fever, chills, rigors, hypotension, urticaria, angioedema and other symptoms (see section 4.8). 
Značilni zanje so bili pljučni dogodki in v nekaterih primerih hiter razpad tumorja z značilnostmi sindroma razpada tumorja, poleg zvišane telesne temperature, mrzlice, drgetanja, hipotenzije, urtikarije, angioedema in drugih simptomov (glejte poglavje 4.8).
Table 13 Radiographic outcomes at 1 year (mITT population) 
Radiološki izidi po 1 letu v študiji 1 (populacija, ki so jo nameravali zdraviti).
The most frequently reported serious infection in the rituximab group was pneumonia at a frequency of 4%. 
Najpogosteje zabeležena okužba v skupini bolnikov, ki so prejemali rituksimab, je bila pljučnica; njena pogostnost je bila 4%.
At month 28, major relapse (defined by the reappearance of clinical and/or laboratory signs of vasculitis activity ([BVAS] > 0) that could lead to organ failure or damage or could be life threatening) occurred in 3 patients (5%) in the rituximab group and 17 patients (29%) in the azathioprine group (p=0.0007). 
Rezultati Po 28 mesecih so hujši recidiv (opredeljen kot ponoven pojav kliničnih in/ali laboratorijskih znakov aktivnosti vaskulitisa ([BVAS] > 0), ki bi lahko povzročil odpoved organa ali okvaro ali bi lahko bil življenjsko nevaren) zabeležili pri 3 bolnikih (5 %) v skupini z zdravilom rituksimab in pri 17 bolnikih (29 %) v skupini z azatioprinom (p = 0,0007).
Rituximab + Prednisone N=38 
rituksimab + prednizon n = 38
Age, gender and WHO performance status had no effect on the pharmacokinetics of rituximab. 
Starost, spol in stanje zmogljivosti po SZO niso vplivali na farmakokinetiko rituksimaba.
These reactions are less likely to happen after the second infusion. 
Po drugi infuziji je pojav teh reakcij manj verjeten.
In patients treated with rituximab, the occurrence of pre-existing ischemic cardiac conditions becoming symptomatic, such as angina pectoris, has been observed, as well as atrial fibrillation and flutter. 
Pri bolnikih, ki so se zdravili z rituksimabom, so opazili simptomatiko že obstoječe ishemične bolezni srca, kot je angina pektoris, ter tudi atrijsko fibrilacijo in undulacijo.
Concentrate for solution for infusion 100 mg / 10 mL 
koncentrat za raztopino za infundiranje 100 mg/10 ml
• feeling restless, problems falling asleep, 
nemir, bolnik težko zaspi,
The overall safety profile of rituximab in rheumatoid arthritis is based on data from patients from clinical trials and from post-marketing surveillance. 
Celokupen varnostni profil rituksimaba pri revmatoidnem artritisu je osnovan na podatkih bolnikov iz kliničnih preskušanj in spremljanja po prihodu zdravila na trg.
IgG immunoglobulins are known to cross the placental barrier. 
Imunoglobulini IgG lahko prehajajo skozi placentno pregrado.
Laboratory evaluations 
Laboratorijske preiskave
Observation N=513 
Opazovanje rituksimab n = 513
Patients treated with Ritemvia must be given the patient alert card with each infusion. 
Bolniki, ki prejemajo zdravilo Ritemvia, morajo ob vsaki infuziji dobiti opozorilno kartico.
Adverse drug reactions presented in Table 5 were adverse events which occurred at a rate of ≥ 5% among rituximab-treated PV patients, with a ≥ 2% absolute difference in incidence between the rituximab-treated group and the standard-dose prednisone group up to month 24. 
V preglednici 5 prikazani neželeni učinki so tisti, ki so se med bolniki z navadnim pemfigusom, zdravljenimi z zdravilom rituksimab, pojavili z ≥ 5-odstotnim deležem, absolutna razlika v njihovi pojavnosti med skupino z zdravilom rituksimab in skupino s standardnim odmerkom prednizona pa je bila do 24. meseca ≥ 2%.
Concomitant/sequential use of other DMARDs in rheumatoid arthritis The concomitant use of rituximab and anti-rheumatic therapies other than those specified under the rheumatoid arthritis indication and posology is not recommended. 
Sočasna/zaporedna uporaba drugih DMARD pri revmatoidnem artritisu Sočasna uporaba zdravila rituksimab in zdravil za zdravljenje revmatičnih bolezni, razen omenjenih v indikaciji in odmerjanju za revmatoidni artritis, ni priporočljiva.
The prepared infusion solution of rituximab in 5% glucose solution is physically and chemically stable for 24 hours at 2 °C - 8 °C and subsequently 12 hours at room temperature (not more than 30 °C). 
Pripravljena infuzijska raztopina rituksimaba v 5-% raztopini D-glukoze je fizikalno in kemijsko stabilna 24 ur pri temperaturi 2 do 8 °C in nato še 12 ur pri sobni temperaturi (pri temperaturi do 30 °C).
Cardiac disorders angina pectoris, atrial fibrillation, heart failure, 
Srčne bolezni angina pektoris, atrijska fibrilacija,
In the CLL first-line study, Binet stage C patients experienced more adverse events in the R-FC arm compared to the FC arm (R-FC 83% vs. FC 71%). 
V študiji pri bolnikih s KLL v prvi liniji zdravljenja so imeli bolniki s stopnjo C po Binetu več neželenih dogodkov v skupini R-FC v primerjavi s skupino FC (R-FC 83% proti FC 71%).
The prepared infusion solution of rituximab in 0.9% sodium chloride solution is physically and chemically stable for 30 days at 2 °C - 8 °C and subsequently 24 hours at room temperature (not more than 30 °C). 
Pripravljena infuzijska raztopina rituksimaba v 0.9-% raztopini natrijevega klorida je fizikalno in kemijsko stabilna 30 dni pri temperaturi 2 do 8 °C in nato še 24 ur pri sobni temperaturi (pri temperaturi do 30 °C).
• blood clotting problems, decrease of red blood cell production and increase of red blood cell destruction (aplastic haemolytic anaemia), swollen or enlarged lymph nodes 
motnje strjevanja krvi, zmanjšano nastajanje rdečih krvnih celic in povečano propadanje rdečih krvnih celic (aplastična hemolitična anemija), oteklost ali povečanje bezgavk,
Following induction of remission with Ritemvia, maintenance treatment should be initiated no sooner than 16 weeks after the last Ritemvia infusion. 
Po indukciji remisije z zdravilom Ritemvia se vzdrževalnega zdravljenja ne sme začeti prej kot 16 tednov po zadnji infuziji zdravila Ritemvia.
Hepatitis B Infections 
Okužbe s hepatitisom B
Psychiatric disorders depression, anxiety 
Psihiatrične motnje depresija, anksioznost
Ritemvia is indicated for the treatment of patients with CD20 positive diffuse large B cell non-Hodgkin's lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy. 
Zdravilo Ritemvia je indicirano za zdravljenje bolnikov s CD20-pozitivnim difuznim velikoceličnim B ne-Hodgkinovim limfomom v kombinaciji s kemoterapijo CHOP (ciklofosfamid, doksirubicin, vinkristin, prednizolon).
Depending on the severity of the IRR and the required interventions, temporarily or permanently discontinue rituximab. 
Glede na resnost z infuzijo povezanih reakcij in potrebne ukrepe, je treba zdravilo rituksimab ukiniti ali ga začasno prekiniti.
The incidence of IRRs declined with subsequent infusions. 
Incidenca reakcij, povezanih z infuzijo, je bila pri nadaljnjih infuzijah manjša.
Ritemvia should be administered on day 1 of each chemotherapy cycle, after intravenous administration of the glucocorticoid component of the chemotherapy if applicable. 
Zdravilo Ritemvia je treba dajati prvi dan vsakega cikla kemoterapije po uporabi glukokortikoidne sestavine kemoterapije, če jo shema vsebuje.